Wealthfront Advisers
RPRX icon

Wealthfront Advisers’s Royalty Pharma RPRX Stock Holding History

Wealthfront Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-202,283
Closed -$7.29M – 1022
2025
Q2 		$7.29M Buy
202,283
+7,507
+4% +$249K 0.02% 288
2025
Q1 		$6.06M Buy
194,776
+5,841
+3% +$185K 0.02% 310
2024
Q4 		$4.82M Buy
188,935
+178,173
+1,656% +$4.72M 0.01% 338
2024
Q3 		$304K Buy
+10,762
New +$298K ﹤0.01% 832
2024
Q2 		– Sell
-33,821
Closed -$1.03M – 892
2024
Q1 		$1.03M Sell
33,821
-33,185
-50% -$978K ﹤0.01% 610
2023
Q4 		$1.88M Sell
67,006
-8,831
-12% -$243K 0.01% 476
2023
Q3 		$2.06M Buy
75,837
+30,489
+67% +$906K 0.01% 417
2023
Q2 		$1.39M Sell
45,348
-7,363
-14% -$249K 0.01% 492
2023
Q1 		$1.9M Buy
52,711
+10,082
+24% +$374K 0.01% 422
2022
Q4 		$1.68M Buy
42,629
+32,875
+337% +$1.37M 0.01% 440
2022
Q3 		$392K Buy
9,754
+2,580
+36% +$110K ﹤0.01% 651
2022
Q2 		$302K Buy
+7,174
New +$294K ﹤0.01% 684

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wealthfront Advisers's RPRX Position: Q3 2025 in Review

Wealthfront Advisers sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 202,283 shares — an estimated $7.29M sold.

Wealthfront Advisers first reported a position in RPRX in Q2 2022 and held it in 12 quarters. The position peaked at $7.29M in Q2 2025. 488 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • Wealthfront Advisers reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • Wealthfront Advisers sold 202,283 Royalty Pharma shares in Q3 2025, an estimated $7.29M.
  • Wealthfront Advisers first reported a position in Royalty Pharma in Q2 2022 and held it in 12 quarters.
  • Wealthfront Advisers's Royalty Pharma position peaked at $7.29M in Q2 2025.
  • 488 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Wealthfront Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.